[Translation] A single-dose, fasting, randomized, open-label, two-cycle, double-crossover bioequivalence study pilot trial of fenofibrate tablets (III) in healthy subjects
1. 验证分析方法;2 评估变异程度;3 优化采血时间;4 初步评估单次口服由广州柏赛罗药业有限公司生产的0.16g非诺贝特片(Ⅲ)和法国利博福尼制药公司非诺贝特片(Ⅲ)(0.16g/片)的相对生物利用度,评价两制剂间的生物等效性。
[Translation] 1. Validate the analysis method; 2. Evaluate the degree of variation; 3. Optimize the blood collection time; The relative bioavailability of fenofibrate tablets (Ⅲ) (0.16g/tablet), and the bioequivalence between the two preparations was evaluated.